CDTX · Cidara Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | - | $0 | $302.0K | $8.46M | - | $12.72M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $35.53M | $24.82M | $24.60M | - | $12.43M | $6.66M | $11.59M | - | $17.33M | $17.14M |
| SG&A | $8.10M | $6.50M | $6.18M | - | $4.96M | $4.75M | $6.00M | - | $3.56M | $3.31M |
| Total Operating Expenses | $88.63M | $27.38M | $25.27M | - | $17.39M | $96.29M | $19.15M | - | $21.27M | $20.45M |
| D&A | - | - | $36.0K | - | - | - | $36.0K | - | - | - |
| Operating Income | ($88.63M) | ($27.38M) | ($25.27M) | - | ($17.39M) | ($95.98M) | ($10.69M) | - | ($8.55M) | ($12.83M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | - | $0 | $0 | $0 | - | $230.0K | $0 |
| Net Income | ($83.23M) | ($25.72M) | ($23.48M) | - | ($15.98M) | ($91.21M) | ($10.33M) | - | ($8.17M) | ($12.36M) |
| EPS - Basic | ($3.10) | ($1.65) | ($1.66) | - | ($2.45) | ($19.99) | ($2.28) | - | ($0.09) | ($0.14) |
| EPS - Diluted | ($3.10) | ($1.65) | ($1.66) | - | ($2.45) | ($19.99) | ($2.28) | - | ($0.09) | ($0.14) |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $293.65M | $510.57M | $168.15M | $189.82M | $127.39M | $164.37M | $29.02M | $35.78M | $48.67M | $50.43M |
| Accounts Receivable | $1.86M | $1.86M | $1.69M | $1.69M | $1.70M | $2.35M | $7.28M | $16.25M | $2.85M | $5.48M |
| Inventory | - | - | - | - | - | - | $7.27M | $6.10M | $2.47M | $0 |
| Accounts Payable | $4.35M | $2.21M | $4.90M | $3.61M | $2.97M | $2.29M | $5.05M | $3.77M | $3.66M | $1.90M |
| Current Assets | $442.82M | $531.79M | $188.85M | $210.74M | $156.77M | $168.59M | $46.83M | $60.85M | $57.70M | $62.24M |
| Total Assets | $518.65M | $534.33M | $191.73M | $214.80M | $162.33M | $173.36M | $52.72M | $67.03M | $63.47M | $67.99M |
| Current Liabilities | $95.84M | $32.32M | $48.81M | $49.55M | $44.34M | $39.64M | $65.42M | $67.42M | $35.62M | $31.42M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $96.26M | $33.15M | $50.05M | $51.49M | $46.70M | $42.42M | $70.50M | $75.24M | $55.43M | $52.57M |
| Stockholders' Equity | $422.39M | $501.17M | $141.68M | $163.31M | $115.63M | $130.94M | ($17.78M) | ($8.21M) | $8.04M | $15.41M |
| Retained Earnings | ($743.69M) | ($660.46M) | ($634.74M) | ($611.26M) | ($558.95M) | ($542.97M) | ($451.76M) | ($441.43M) | ($424.29M) | ($416.11M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($21.95M) | - | - | - | ($6.64M) | - | - | - |
| Investing Cash Flow | - | - | $185.0K | - | - | - | ($23.0K) | - | - | - |
| Financing Cash Flow | - | - | $77.0K | - | - | - | ($93.0K) | - | - | - |
| CapEx | - | - | $0 | - | - | - | $23.0K | - | - | - |
| Free Cash Flow | - | - | ($21.95M) | - | - | - | ($6.67M) | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | -31782.8% | -126.3% | - | -67.3% | - |
| EBITDA margin | - | - | - | - | - | - | -125.9% | - | - | - |
| Net margin | - | - | - | - | - | -30201.7% | -122.0% | - | -64.3% | - |
| Free cash flow margin | - | - | - | - | - | - | -78.8% | - | - | - |
| FCF / Net income | - | - | 0.93 | - | - | - | 0.65 | - | - | - |
| R&D / Revenue | - | - | - | - | - | 2204.3% | 137.0% | - | 136.3% | - |
| SG&A / Revenue | - | - | - | - | - | 1571.5% | 70.9% | - | 28.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -16.0% | -4.8% | -12.2% | - | -9.8% | -52.6% | -19.6% | - | -12.9% | -18.2% |
| Return on equity | -19.7% | -5.1% | -16.6% | - | -13.8% | -69.7% | 58.1% | - | -101.7% | -80.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.62 | 16.45 | 3.87 | 4.25 | 3.54 | 4.25 | 0.72 | 0.90 | 1.62 | 1.98 |
| Quick ratio | 4.62 | 16.45 | 3.87 | 4.25 | 3.54 | 4.25 | 0.60 | 0.81 | 1.55 | 1.98 |
| Cash ratio | 3.06 | 15.80 | 3.45 | 3.83 | 2.87 | 4.15 | 0.44 | 0.53 | 1.37 | 1.61 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.23 | 1.07 | 1.35 | 1.32 | 1.40 | 1.32 | -2.96 | -8.16 | 7.90 | 4.41 |
| Liabilities / Assets | 0.19 | 0.06 | 0.26 | 0.24 | 0.29 | 0.24 | 1.34 | 1.12 | 0.87 | 0.77 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.16 | - | 0.20 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | 2839d | 314d | - | 82d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -100.0% | -100.0% | - | -100.0% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -409.5% | 71.5% | -136.4% | - | -103.3% | -648.1% | - | - | - | 2.2% |
| Net income growth (YoY) | -420.7% | 71.8% | -127.4% | - | -95.6% | -638.1% | - | - | - | 5.8% |
| EPS growth (YoY) | -26.5% | 91.7% | 27.2% | - | -2622.2% | -14178.6% | - | - | - | 26.3% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -229.2% | - | - | - | 39.3% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 265.3% | 282.8% | - | - | 1338.5% | 749.5% | - | -182.7% | -11.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$1.27M totalReportable Segment$1.27M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Cidara Therapeutics against the 5 most active filers in the same SIC group.